InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.
Previously mechanistic model predicting concentration of monoclonal antibodies (mAbs) and target occupancy in cerebrospinal fluid was developed by InSysBio in collaboration with discoveric bio alpha. The further project expansion aims to use the model to support first-in-human study of NIDB-3101 leveraging cyno-to-human translation and available published clinical data as benchmarks.
Jean-Philippe Courade, CSO of discoveric bio alpha, comments on the project extension, “We were inspired to experience InSysBio’s cutting-edge mechanistic modeling approach during our first collaboration. Now we are excited to continue the project that will provide us with a range of new predictions to efficiently advance through the next stages of our antibody development”.
Oleg Demin Jr, Scientific Director, InSysBio, highlights, “We are encouraged by the opportunity to implement our expertise and solutions to further unleash the potential of the model. With its help we will support the selection of the starting dose and pharmacologically active dose to optimize first-in-human study”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
About discoveric bio alpha
discoveric bio alpha is a privately owned company part of a group of three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. It is located in Pfäffikon, Switzerland. For more information, visit https://www.discovericbio.com/
| ← | February 2022 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
1.
17 Feb 2022 15:58
InSysBio to present its poster at Tau2022 Global Conference
InSysBio announces its participation in Tau2022 Global Conference. Tau2022 is held virtually on February 22-23, 2022. InSysBio team presents a poster within its frames
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
1.
24 Feb 2022 15:27
InSysBio to participate in ASCPT 2022
InSysBio announces its participation in ASCPT 2022 Annual Meeting which is to be held virtually March 16-18, 2022. InSysBio is going to give a talk in frames of its Micro-Theater Session with live Q&A which is scheduled for 3:30 PM ET, Thursday, March 17th. InSysBio team will also present two posters
|
25
|
26
|
27
|
|
28
| ||||||
Thank you for your message! We will get back to you shortly.
